Post by
Eoganacht on Jan 01, 2024 7:12pm
I think we're good
As of 29 Nov there were 43 evaluable patients at 450 days and 35% had achieved a CR. This is considerably better than the currently approved treatments and better than or almost as good as the, as yet unapproved, combo treatments that subject patients to an unending series of treatments which are less and less efficacious over time.
As we move into the second half of the trial we should see even better 450 results as more PIs overcome the "learning curve" mentioned by Dr. Kulkarni and the effects of the results of the first 12 undertreated patients are diluted.
By the end of the trial we should be far ahead of any competition - in durable efficacy, number of treatments safety, and convenience.
This should be obvious to anyone paying close attention and I believe there are some big pharmas paying very close attention.
Comment by
N0taP00p on Jan 02, 2024 3:52pm
Eoganacht: Reuters has a new story about record drug approvals by the FDA in 2023. Search for "US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery". Hoping one of those for 2024 is Ruvidar, given fast-track designation and the data. End of Q1 for both BTD and AA sure would be nice.